Brand Names:
Aridol, Bronchitol, Cystosol, Osmitrol, Sag-M


Drug Type: Diuretic

Mannitol

Mannitol is an osmotic diuretic used to reduce intracranial and intraocular pressure for treatment of cerebral edema, especially after head trauma.

Mannitol works by elevating blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. It is an antiglaucoma agent and used for the promotion of diuresis before irreversible renal failure becomes established.
  • 0.25-2 mg/kg q24h IV (slow bolus)
  • Amikacin: The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Amikacin.
  • Amoxicillin: Mannitol may increase the excretion rate of Amoxicillin which could result in a lower serum level and potentially a reduction in efficacy.
  • Bacitracin: The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Bacitracin.
  • Butorphanol: The therapeutic efficacy of Mannitol can be decreased when used in combination with Butorphanol.
  • Carprofen: The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Carprofen.
  • Cefadroxil, Cephalexin, Cefpodoxime, Cefapirin, Cefalotin: The risk or severity of nephrotoxicity can be increased when Mannitol is combined.
  • Diazepam: Mannitol may increase the excretion rate of Diazepam which could result in a lower serum level and potentially a reduction in efficacy.
  • Doxycycline: Mannitol may increase the excretion rate of Doxycycline which could result in a lower serum level and potentially a reduction in efficacy.
  • Enalapril: The risk or severity of adverse effects can be increased when Enalapril is combined with Mannitol.
  • Erythromycin: The serum concentration of Mannitol can be increased when it is combined with Erythromycin.
  • Epinephrine: The risk or severity of Cardiac Arrhythmia can be increased when Epinephrine is combined with Mannitol.
  • Folic acid: Mannitol may increase the excretion rate of Folic acid which could result in a lower serum level and potentially a reduction in efficacy.
  • Furosemide: The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Furosemide.
  • Gentamicin: The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Gentamicin.
  • Magnesium sulfate: The risk or severity of adverse effects can be increased when Mannitol is combined with Magnesium sulfate.
  • Meloxicam: The therapeutic efficacy of Mannitol can be decreased when used in combination with Meloxicam.
  • Mineral oil: The risk or severity of adverse effects can be increased when Mannitol is combined with Mineral oil.
  • Neomycin: The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Neomycin.
  • Prednisolone phosphate: The serum concentration of Prednisolone phosphate can be increased when it is combined with Mannitol.
  • Prednisone: Mannitol may increase the excretion rate of Prednisone which could result in a lower serum level and potentially a reduction in efficacy.
  • Pyrantel:Mannitol may increase the excretion rate of Pyrantel which could result in a lower serum level and potentially a reduction in efficacy.
  • Selenium: Mannitol may increase the excretion rate of Selenium which could result in a lower serum level and potentially a reduction in efficacy.
  • Streptomycin: The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Streptomycin.
  • Sulfadiazine: Mannitol may increase the excretion rate of Sulfadiazine which could result in a lower serum level and potentially a reduction in efficacy.
  • Tetracycline: Mannitol may increase the excretion rate of Tetracycline which could result in a lower serum level and potentially a reduction in efficacy.
  • Thiabendazole:Mannitol may increase the excretion rate of Thiabendazole which could result in a lower serum level and potentially a reduction in efficacy.
  • Tiludronic acid: The risk or severity of nephrotoxicity and hypocalcemia can be increased when Mannitol is combined with Tiludronic acid.
  • Chondroitin sulfate: Mannitol may increase the excretion rate of Chondroitin sulfate which could result in a lower serum level and potentially a reduction in efficacy.
  • Fish oil: The risk or severity of hyperkalemia can be increased when Mannitol is combined with Fish oil.
  • Pyridoxine: Mannitol may increase the excretion rate of Pyridoxine which could result in a lower serum level and potentially a reduction in efficacy.

Popular Health Tools

Switch Animal